Timing is Everything

[stevo51]

ATNM: Presently there are (only) 2 analysts following Actinium Pharmaceuticals, both with a “buy” rating and an average price target of $16/share. As Iomab-B enters Phase 3 trials and more data from clinical trials of Actimab-A become public, (as soon as next week), we believe additional analysts will begin following the company. Simply put, the market for Actinium’s drug pipeline is too big and the results from clinical trials have been too good to be overlooked much longer by analysts.

We see Actinium Pharmaceuticals as a STRONG BUY at current prices, and have a 12 month price target of $12/share. We believe this is a very realistic and conservative target, and we look forward to following Actinium’s developments closely in the coming months and sharing them with our subscribers.